Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP VERHOEF, Gregor
ROBAK, Tadeusz
HUANG, Huiqiang
DRACH, Johannes
PEI, Lixia
ROONEY, Brendan
CAKANA, Andrew
VELDE, Helgi van de
CAVALLI, Franco 2017
dc.identifier.citation HAEMATOLOGICA, v.102, n.5, p.895-902, 2017
dc.identifier.issn 0390-6078
dc.description.abstract In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P<0.001). This post-hoc analysis evaluated the association between the improved outcomes and quality of responses achieved with VR-CAP versus R-CHOP in LYM-3002. Patients were randomized to six to eight 21-day cycles of VR-CAP or R-CHOP. Outcomes included progression-free survival, duration of response (both assessed by an independent review committee), and time to next anti-lymphoma treatment, evaluated by response (complete response/unconfirmed complete response and partial response), MIPI risk status, and maximum reduction of lymph-node measurements expressed as the sum of the product of the diameters. Within each response category, the median progression-free survival was longer for patients given VR-CAP than for those given R-CHOP (complete response/unconfirmed complete response: 40.9 versus 19.8 months; partial response: 17.1 versus 11.7 months, respectively); similarly, the median time to next anti-lymphoma treatment was longer among the patients given VR-CAP than among those treated with R-CHOP (complete response/unconfirmed complete response: not evaluable versus 26.6 months; partial response: 35.3 versus 24.3 months). Within the complete/unconfirmed complete and partial response categories, improvements in progression-free survival, duration of response and time to next anti-lymphoma treatment were more pronounced in patients with low- and intermediate-risk MIPI treated with VR-CAP than with R-CHOP. In each response category, more VR-CAP than R-CHOP patients had a sum of the product of the diameters nadir of 0 during serial radiological assessments. Results of this post-hoc analysis suggest a greater duration and quality of response in patients treated with VR-CAP in comparison with those treated with R-CHOP, with the improvements being more evident in patients with low-and intermediate-risk MIPI. LYM-3002 NCT00722137.
dc.description.sponsorship · Millennium Pharmaceuticals, Inc.
· Janssen Global Services, LLC.
dc.language.iso eng
dc.relation.ispartof Haematologica
dc.rights openAccess
dc.subject.other prognostic index; guidelines; rituximab; survival; criteria; therapy; network
dc.title Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
dc.type article
dc.rights.holder Copyright FERRATA STORTI FOUNDATION LIM/31
dc.identifier.doi 10.3324/haematol.2016.152496
dc.identifier.pmid 28183846
dc.type.category original article
dc.type.version publishedVersion PEREIRA, Juliana:FM:MCM · VERHOEF, Gregor:Univ Hosp Leuven, Leuven, Belgium
· ROBAK, Tadeusz:Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland
· HUANG, Huiqiang:Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
· PYLYPENKO, Halyna:Cherkassy Reg Oncol Ctr, Cherkassy, Ukraine
· SIRITANARATKUL, Noppadol:Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok, Thailand
· DRACH, Johannes:Univ Vienna, Vienna Gen Hosp, Vienna, Austria
· MAYER, Jiri:Masaryk Univ Hosp Brno, Brno, Czech Republic
· OKAMOTO, Rumiko:Chibanishi Gen Hosp, Chiba, Japan; Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
· PEI, Lixia:Janssen Res & Dev LLC, Raritan, NJ USA
· ROONEY, Brendan:Janssen Res & Dev, High Wycombe, Bucks, England
· CAKANA, Andrew:Janssen Res & Dev, High Wycombe, Bucks, England
· VELDE, Helgi van de:Millennium Pharmaceut Inc, Boston, MA USA
· CAVALLI, Franco:Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, Bellinzona, Ticino, Switzerland WOS:000402490900026 2-s2.0-85018971634 PAVIA ITALY
hcfmusp.relation.reference · Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403
· Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800
· Dreyling M, 2013, ANN ONCOL, V24, P857, DOI 10.1093/annonc/mds643
· Dreyling M, 2015, NAT REV CLIN ONCOL, V12, P377, DOI 10.1038/nrclinonc.2015.101
· Frosch Z, 2015, CL LYMPH MYELOM LEUK, V15, P92, DOI 10.1016/j.clml.2014.07.017
· Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331
· Hoster E, 2014, J CLIN ONCOL, V32, P1338, DOI 10.1200/JCO.2013.52.2466
· Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288
· Howlader N, 2015, SEER CANC STAT REV 1
· Juweid ME, 2005, J CLIN ONCOL, V23, P4652, DOI 10.1200/JCO.2005.01.891
· McKay P, 2012, BRIT J HAEMATOL, V159, P405, DOI 10.1111/bjh.12046
· Millennium Pharmaceuticals Inc, 2014, VELCADE BORT INJ SUB
· Pott C, 2010, BLOOD, V115, P3215, DOI 10.1182/blood-2009-06-230250
· Robak T, 2015, NEW ENGL J MED, V372, P944, DOI 10.1056/NEJMoa1412096
· Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2
· Smith A, 2015, BRIT J CANCER, V112, P1575, DOI 10.1038/bjc.2015.94
· Zhou YH, 2008, CANCER, V113, P791, DOI 10.1002/cncr.23608
dc.description.index MEDLINE
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 0 Brasil Bélgica Polônia China Ucrânia Tailândia Áustria República Tcheca Suíça Japão Estados Unidos Inglaterra

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account